Archives
-
JNJ-26481585 (Quisinostat) Assay Guide
2026-10-01
A scenario-based guide to using JNJ-26481585 (Quisinostat), SKU A4090, in cell viability, proliferation, apoptosis, and drug-resistance studies. It connects HDAC biology with practical dosing, solvent control, orthogonal readouts, and evidence-based product selection.
-
JNK-IN-7: Selective JNK Inhibitor Guide
2026-10-01
JNK-IN-7 is a selective JNK inhibitor that targets JNK1, JNK2, and JNK3 and suppresses c-Jun phosphorylation through covalent kinase engagement. Its defined biochemical profile and pathway-specific cellular effects support MAPK signaling pathway research, apoptosis assay design, and innate immune signaling modulation.
-
Annexin V-HF647/PI Apoptosis Kit in ESCC
2026-09-30
Learn how the Annexin V-HF647/PI Apoptosis Kit can translate HOXC9–AKT/mTOR biology into a rigorous apoptosis measurement strategy in esophageal squamous cell carcinoma. This guide emphasizes interpretation, controls, and assay design rather than treating fluorescence as a standalone mechanistic conclusion.
-
Live-Dead Cell Staining Kit I for Neuronal Assays
2026-09-30
Learn how Calcein AM/PI staining converts neuronal injury experiments into interpretable live, dead, and membrane-compromised cell profiles. This workflow combines practical staining parameters, image-analysis safeguards, and troubleshooting for mammalian cytotoxicity studies inspired by cerebral hemorrhage research.
-
ALC-0159: From LNP Design to Immunotherapy Assays
2026-09-29
Explore how ALC-0159 PEG lipid supports formulation-aware mRNA delivery studies and how recent cancer immunotherapy evidence can guide assay design. This article separates particle behavior, innate signaling, antigen expression, and checkpoint biology without assuming that every LNP uses the same lipid composition.
-
Alternariol for Mycotoxin and Fibrosis Research
2026-09-29
Alternariol (AOH) provides a chemically defined way to connect foodborne toxin exposure with hepatic stellate-cell activation, apoptosis, cytoskeletal remodeling, and metabolic clearance. This workflow combines careful compound handling with phenotype-first assays, CYP1A1/CYP1A2 studies, and CotA-based detoxification research.
-
0.4% Trypan Blue Solution Workflow Guide
2026-09-28
0.4% Trypan Blue Solution supports rapid cell viability measurement and live/dead cell discrimination during cell counting and cytotoxicity workflows. It is intended for research use, not diagnostic or medical applications, and it should not be used alone to identify specific cell-death mechanisms.
-
0.4% Trypan Blue Solution: Practical Workflow
2026-09-28
0.4% Trypan Blue Solution supports rapid cell viability measurement by staining cells with compromised membranes, helping researchers distinguish them from unstained cells in routine counts and cytotoxicity workflows. It is for scientific research use only, not diagnostic or medical use, and its readout reflects membrane integrity rather than a specific cell-death mechanism.
-
JZL184: MAGL Inhibition for Pain Research
2026-09-27
JZL184 lets researchers test whether MAGL-dependent 2-AG breakdown contributes to neuronal and pain-related outcomes, with target engagement measured alongside behavior. A practical workflow connects the compound to inflammatory-pain models while clearly distinguishing its mechanism from cannabidiol findings.
-
Dimetridazole: Sensor and Microbial Research Workflows
2026-09-26
Dimetridazole supports two distinct research paths: ultrasensitive electrochemical detection and carefully controlled studies of microbial susceptibility, virulence, and biofilms. A molecularly imprinted sensor study reported a 0.1 nM detection limit, while antimicrobial experiments require organism-specific controls and should not be interpreted as evidence of clinical efficacy.
-
HOXC9 Drives ESCC Growth Through AKT/mTOR Signaling
2026-09-25
The study links elevated HOXC9 in esophageal squamous cell carcinoma (ESCC) with increased proliferation and reduced mitochondria-dependent apoptosis, implicating AKT/mTOR signaling in these effects. Its combination of patient-tissue analysis, cell-based perturbations, pathway inhibition, and xenograft experiments supports HOXC9 as a candidate biomarker and a target for further validation—not yet a clinically established diagnostic or treatment target.
-
Panobinostat Targets MLL-Rearranged ALL In Vivo
2026-09-25
In xenograft models, panobinostat reduced leukaemia burden and extended survival in MLL-rearranged acute lymphoblastic leukaemia, while cell-based analyses implicated suppression of the RNF20/RNF40/WAC–H2B ubiquitination pathway. The study links HDAC inhibition to disruption of a disease-relevant epigenetic maintenance mechanism, offering a rationale for further preclinical investigation rather than establishing a clinical treatment strategy.
-
Salvianolic Acid B in Pulmonary Fibrosis Research
2026-09-24
Salvianolic acid B offers a focused way to test whether lowering LH2 expression can alter collagen remodeling in pulmonary fibrosis models. This practical guide links compound handling to cell-based workflows, orthogonal readouts, and troubleshooting—while distinguishing suggested pilot conditions from findings reported in the study.
-
DiscoveryProbe Natural Product Library Plus for HTS
2026-09-24
Practical guidance for planning cell-based screens with DiscoveryProbe™ Natural Product Library Plus (Catalog No. L1039P), including compound handling, assay controls, and interpretation of natural-product hits. The article connects product specifications with published Cryptosporidium findings while distinguishing library capabilities from study results.
-
Tricine-SDS-PAGE Electrophoresis System Gel Guide
2026-09-23
This kit addresses the poor resolution conventional Tris-SDS-PAGE can provide for small proteins and peptides, with product specifications covering molecules in the 1–10 kDa range. It is intended for research gel preparation and electrophoresis workflows, not diagnostic or medical use; the supplied information does not specify run conditions or a complete sample-preparation protocol.